Chandler Robinson Monopar Therapeutics (MNPR) insider trading activity

Chandler Robinson is Chief Executive Officer of Monopar Therapeutics. Currently has a direct ownership of 73,472 shares of MNPR, which is worth approximately $2.55 Million. The most recent transaction as insider was on Jul 14, 2025, when has been sold 16,800 shares (Common Stock) at a price of $40.0 per share, resulting in proceeds of $672,000. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 73.5K

11.33% 3M change

72.37% 12M change

Total Value Held $2.55 Million

Chandler Robinson Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jul 14 2025	SELL Open market or private sale	$672,000 $40.0 p/Share	16,800 Reduced 18.61%	73,472 Common Stock
Jul 14 2025	BUY Exercise of in-the-money or at-the-money derivatives securities	-	16,800 Added 15.69%	90,272 Common Stock
Jun 30 2025	SELL Payment of exercise price or tax liability	$209,849 $35.78 p/Share	5,865 Reduced 7.39%	73,472 Common Stock
Jun 30 2025	BUY Exercise of conversion of derivative security	-	13,344 Added 14.4%	79,337 Common Stock
Mar 31 2025	SELL Payment of exercise price or tax liability	$43,837 $36.41 p/Share	1,204 Reduced 1.79%	65,993 Common Stock
Mar 31 2025	BUY Exercise of conversion of derivative security	-	4,106 Added 5.76%	67,197 Common Stock
Mar 04 2025	SELL Payment of exercise price or tax liability	$55,760 $31.7 p/Share	1,759 Reduced 2.71%	63,091 Common Stock
Mar 04 2025	BUY Exercise of conversion of derivative security	-	6,002 Added 8.47%	64,850 Common Stock
Dec 31 2024	SELL Payment of exercise price or tax liability	$48,598 $22.0 p/Share	2,209 Reduced 3.62%	58,848 Common Stock
Dec 31 2024	BUY Exercise of conversion of derivative security	-	4,895 Added 7.42%	61,057 Common Stock
Sep 30 2024	SELL Payment of exercise price or tax liability	$12,927 $6.74 p/Share	1,918 Reduced 3.3%	56,162 Common Stock
Sep 30 2024	BUY Exercise of conversion of derivative security	-	4,895 Added 7.77%	58,080 Common Stock
Jun 30 2024	SELL Payment of exercise price or tax liability	$6,339 $0.73 p/Share	8,684 Reduced 3.16%	265,922 Common Stock
Jun 30 2024	BUY Exercise of conversion of derivative security	-	24,476 Added 8.18%	274,606 Common Stock
May 28 2024	BUY Exercise of in-the-money or at-the-money derivatives securities	-	84,000 Added 25.14%	250,130 Common Stock
Mar 31 2024	SELL Payment of exercise price or tax liability	$4,876 $0.68 p/Share	7,172 Reduced 4.14%	166,130 Common Stock
Mar 31 2024	BUY Exercise of conversion of derivative security	-	24,474 Added 12.37%	173,302 Common Stock
Jan 01 2024	SELL Payment of exercise price or tax liability	$791 $0.34 p/Share	2,327 Reduced 1.54%	148,828 Common Stock
Jan 01 2024	BUY Exercise of conversion of derivative security	-	6,724 Added 4.26%	151,155 Common Stock
Dec 31 2023	SELL Payment of exercise price or tax liability	$2,879 $0.34 p/Share	8,469 Reduced 5.54%	144,431 Common Stock
Dec 31 2023	BUY Exercise of conversion of derivative security	-	24,474 Added 13.8%	152,900 Common Stock
Sep 30 2023	SELL Payment of exercise price or tax liability	$4,446 $0.62 p/Share	7,172 Reduced 5.29%	128,426 Common Stock
Sep 30 2023	BUY Exercise of conversion of derivative security	-	24,474 Added 15.29%	135,598 Common Stock
Jun 30 2023	SELL Payment of exercise price or tax liability	$8,831 $0.86 p/Share	10,269 Reduced 8.46%	111,124 Common Stock
Jun 30 2023	BUY Exercise of conversion of derivative security	-	35,039 Added 22.4%	121,393 Common Stock

Chandler Robinson

Chief Executive Officer

Wilmette, IL

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells MNPR shares.

Notify only if

Value

Insider Trading

Get notified when an Monopar Therapeutics insider buys or sells MNPR shares.

Notify only if

Operation

Value

Type

News

Receive news related to Monopar Therapeutics

Track Activities on MNPR

Account